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Abstract
Objective: Despite	long‐standing	safe	and	effective	use	of	immunoglobulin	replace‐
ment	therapy	(IgRT)	 in	primary	 immunodeficiency,	clinical	data	on	IgRT	in	patients	
with	secondary	 immunodeficiency	 (SID)	due	to	B‐cell	 lymphoproliferative	diseases	
are	 limited.	Here,	we	examine	 the	correlation	between	approved	 IgRT	 indications,	
treatment	recommendations,	and	clinical	practice	in	SID.
Methods: An	international	online	survey	of	230	physicians	responsible	for	the	diag‐
nosis	of	SID	and	the	prescription	of	IgRT	in	patients	with	hematological	malignancies	
was	conducted.
Results: Serum	immunoglobulin	was	measured	in	83%	of	patients	with	multiple	my‐
eloma,	 76%	with	 chronic	 lymphocytic	 leukemia,	 and	 69%	with	 non‐Hodgkin	 lym‐
phoma.	Most	physicians	 (85%)	prescribed	 IgRT	after	≥2	severe	 infections.	 In	 Italy,	
Germany,	Spain,	and	the	United	States,	 immunoglobulin	use	was	above	average	 in	
patients	with	hypogammaglobulinemia,	while	in	the	UK	considerably	fewer	patients	
received	IgRT.	The	use	of	subcutaneous	immunoglobulin	was	highest	in	France	(34%)	
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1  | INTRODUC TION
Hypogammaglobulinemia	 is	 characterized	 by	 a	 decrease	 in	 func‐
tional	or	total	serum	immunoglobulin	(Ig)	levels	and	can	lead	to	im‐
munodeficiency	 associated	 with	 recurrent	 and	 severe	 infections.	
Primary	immunodeficiency	(PID)	is	caused	by	hereditary	and	genetic	
factors,	while	secondary	immunodeficiency	(SID)	is	mainly	a	conse‐
quence	of	a	variety	of	diseases	or	a	side	effect	of	a	range	of	medical	
treatments.1	 Patients	with	 B‐cell	 lymphoproliferative	 diseases	 are	
particularly	 prone	 to	SID	due	 to	 immunodeficiency	 caused	by	 the	
underlying	malignancies	or	the	chemoimmunotherapies	used	to	treat	
the	malignancies.	 Standard	 treatment	protocols	of	NHL,	MM,	 and	
CLL	include	conventional	chemotherapeutics	such	as	cyclophospha‐
mide.	The	spectrum	of	treatments	is	entity‐dependent	and	extended	
by	 targeted	 therapies,	which	 are	 associated	with	 specific	 immune	
defects	 and	 dysregulations.	 Anti‐CD20	 antibodies,	 inducing	 long‐
lasting	B‐cell	deficiency	are	applied	in	B‐cell	NHL	and	CLL,	whereas	
proteasome	inhibitors	(eg,	bortezomib)	and	immunomodulators	(eg,	
lenalidomide)	are	standard	treatments	for	myeloma	patients.2	More	
recent	 targeted	 therapies,	 such	 as	 Bruton’s	 tyrosine	 kinase	 and	
Phosphoinositide	 3‐kinase	δ	 inhibitors,	 are	 broadly	 applied	 in	CLL	
and	 certain	NHL	 subtypes.	 The	 increased	 use	 of	 novel	 B‐cell	 tar‐
geted	therapies,	targeting	differentiation,	function	and	apoptosis	of	
B	cells,	and	CD19‐targeted	chimeric	antigen	receptor	T	cells	(CAR	T)	
as	well	as	the	consequent	increased	survival	rates	in	lymphoprolif‐
erative	diseases	have	led	to	an	increased	diversity	and	incidence	of	
SID	in	hematological	malignancies.3	In	chronic	lymphocytic	leukemia	
(CLL),	up	to	85%	of	patients	develop	hypogammaglobulinemia	and	
infections	are	the	major	cause	of	morbidity	and	mortality,	contribut‐
ing	to	25%‐50%	of	deaths.4‐7	Similarly,	life‐threatening	infections	are	
a	major	cause	of	morbidity	and	mortality	in	multiple	myeloma	(MM),	
with	30%	being	fatal,	and	have	increased	since	the	introduction	of	
novel	therapies.8‐10
Treatment	 of	 immunodeficiency	 by	 immunoglobulin	 replace‐
ment	therapy	 (IgRT)	 is	well	established	 in	PID	due	to	proven	effi‐
cacy	and	safety.11	 In	SID,	despite	being	more	prevalent	 than	PID,	
clinical	 data	 on	 IgRT	 are	 limited.	 Evidence	 for	 the	 use	 of	 IgRT	 in	
CLL	 and	MM	 is	 predominantly	 based	 on	 clinical	 trials	 performed	
20‐30	years	 ago,	 before	 modern	 immunosuppressive	 therapies	
were	 introduced.10,12‐14	 A	 meta‐analysis	 of	 randomized	 trials	 in	
patients	with	CLL	and	MM	reported	that	prophylactic	IgRT	signifi‐
cantly	reduced	major	and	clinically	documented	infections,	but	did	
not	improve	survival.15
Immunoglobulin	 replacement	 therapy	may	 be	 administered	 in‐
travenously	 (IV)	or	subcutaneously	 (SC).	 In	PID,	both	routes	of	ad‐
ministration	 have	 been	 shown	 to	 be	 effective	 and	 safe.	 European	
consensus	proposals	recommend	that	patients	with	PID	should	be	
given	the	choice	between	IVIG	and	SCIG.16,17	In	SID,	the	safety	and	
efficacy	of	SCIG	has	been	demonstrated	 in	case	series	 in	patients	
with	lymphoproliferative	diseases	and	hypogammaglobulinemia.12,18 
SCIG	might	 have	 several	 advantages	 over	 IVIG	 to	 some	 patients.	
SCIG	does	not	require	venous	access	and	allows	more	flexible	and	
convenient	self‐administration	at	home	than	IVIG.12	SCIG	has	been	
associated	with	 an	 improvement	 in	 perceived	 health‐related	 qual‐
ity	of	life.12,19	Additionally,	pharmacokinetics	may	be	preferable,	as	
SCIG	treatment	 leads	to	higher	and	more	stable	 IgG	trough	 levels,	
providing	 patients	 with	 a	 more	 consistent	 protection	 against	 in‐
fections.1,20	The	use	of	SCIG	varies	greatly	between	countries.	For	
example,	in	Scandinavia,	SCIG	is	used	in	80%‐90%	of	PID	patients,	
while	in	Spain,	France,	and	Italy	IVIG	is	used	predominantly.21
In	the	United	States	and	Europe,	national	recommendations	re‐
garding	the	use	of	IgRT	in	hypogammaglobulinemia	associated	with	
hematological	malignancies	extend	 to	conditions	beyond	those	 in‐
cluded	in	the	marketing	authorizations,	although	the	recommenda‐
tions	are	often	not	based	on	strong	evidence	and	vary	widely.11 In 
addition	 to	 promoting	 off‐label	 use,	 differences	 in	 current	 recom‐
mendations	highlight	open	questions	regarding	the	selection	of	pa‐
tients	who	might	benefit	from	IgRT,	such	as	Ig	and	Ig	subclass	serum	
levels,	 testing	 specific	 antibody	 responses,	 test	 immunization,	 and	
infection	history.	In	a	2014	European	consensus	statement,	the	de‐
termination	 of	 serum	 Ig	 concentrations	 and	 the	 levels	 of	 specific	
serum	 antibody	 titers	 in	 response	 to	 vaccination	was	 agreed	 as	 a	
useful	approach	for	patient	selection	in	SID,	although	the	need	for	
more	research	was	acknowledged.17
and	lowest	in	Spain	(19%).	Immunologists	measured	specific	antibody	responses,	per‐
formed	test	immunization,	implemented	IgRT,	and	used	subcutaneous	immunoglobu‐
lin	more	frequently	than	physicians	overall.
Conclusions: The	management	of	SID	in	hematological	malignancies	varied	regionally.	
Clinical	practice	did	not	reflect	treatment	guidelines,	highlighting	the	need	for	robust	
clinical	studies	on	IgRT	in	this	population	and	harmonization	between	countries	and	
disciplines.
K E Y W O R D S
chronic	lymphocytic	leukemia,	hematological	disorders,	immunoglobulins,	infection,	
international	survey,	IVIG,	multiple	myeloma,	non‐Hodgkin	lymphoma,	SCIG,	secondary	
immunodeficiency
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Additional	open	questions	 include	 Ig	dose,	 the	monitoring	of	 Ig	
trough	 levels	during	 therapy,	 and	 criteria	 for	 the	duration	of	 treat‐
ment.	There	is	no	consensus	on	the	duration	of	IgRT.	Re‐evaluation	
of	 the	 effectiveness	 of	 IgRT	 after	 a	 period	 of	 time,	 6	months	 to	 a	
year,	has	been	suggested	by	some	experts.7,22	Agostini	et	al11 recom‐
mended	that	treatment	discontinuation	may	be	considered	in	patients	
with	a	stable	primary	condition	who	have	received	IgRT	for	more	than	
a	year	and	who	have	not	reported	infectious	episodes	during	this	pe‐
riod.	However,	patients	who	continue	to	have	no	B‐cells	or	memory	
B‐cells,	and	those	who	lack	IgA	and	IgM	and	with	conditions	such	as	
CLL,	where	hypogammaglobulinemia	 is	commonly	progressive	over	
time,	are	likely	to	experience	increased	number	of	severe	infections	
due	to	immunodeficiency,	once	prophylaxis	is	stopped.12
In	view	of	these	heterogeneous	treatment	guidelines	for	SID	in	
patients	with	hematological	malignancies,	assessing	current	clinical	
practice	is	of	great	interest.	We	present	an	international	online	sur‐
vey	on	the	daily	clinical	practice	of	SID	diagnosis	and	treatment	in	
hematological	malignancies.	The	aim	of	the	survey	was	to	document	
current	treatment	practices	and	challenges	in	SID	across	countries	
and	to	identify	discrepancies	between	treatment	indications,	treat‐
ment	recommendations,	and	daily	practice	as	well	as	regional	differ‐
ences	in	SID	treatment.
TA B L E  1  Respondent	and	patient	characteristics
Parameter Canada France Germany Italy Spain UK USA Pooled
Number	of	respondents 30 30 30 30 30 30 50 230
Specialty,	n	(%)
Hematologist/
Oncologist
16	(53) 21	(70) 23	(77) 21	(70) 19	(63) 23	(77) 25	(50) 148	(64)
Immunologist 5	(17) 1	(3) 1	(3) 3	(10) 9	(30)a  3	(10) 10	(20) 32	(14)
Internal	medicine 3	(10) 5	(17) 2	(7) 3	(10) 1	(3) 2	(7) 10	(20) 26	(11)
Pediatrician 6	(20) 2	(7) 4	(13) 3	(10) 1	(3) 1	(3) 5	(10) 22	(10)
Other 0	(0) 1	(3) 0	(0) 0	(0) 0	(0) 1	(3) 0	(0) 2	(1)
Clinical	experience,	n	(%)
<5 y 3	(10) 1	(3) 0	(0) 5	(17) 3	(10) 1	(3) 5	(10) 18	(8)
5‐15	y 16	(53) 12	(40) 16	(53) 11	(37) 17	(57) 21	(70) 24	(48) 117	(51)
>15 y 11	(37) 17	(57) 14	(47) 14	(47) 10	(33) 8	(27) 21	(42) 95	(41)
Directly	responsible	for	
diagnosis	of	SID	and	
prescription	of	IgG,	n	(%)
24	(80) 29	(97) 29	(97) 28	(93) 26	(87) 27	(90) 45	(90) 208	(90)
Number	of	patients	cared	for	per	respondent,	n,	median
CLL 15 40 50 30 23 35 20 213
MM 15 39 46 45 21 38 15 219
NHL 10 33 60 50 33 31 25 242
Other	lymphoprolifera‐
tive	diseases
10 20 23 35 20 18 15 141
All	indications 50 132 179 160 97 122 75 815
Patients	cared	for	with	severe	or	recurring	infections,	n	(%	patients)
CLL 398	(34) 335	(28) 655	(35) 730	(29) 461	(38) 280	(21) 496	(25) 3355	(30)
MM 263	(26) 371	(30) 454	(29) 521	(25) 314	(31) 292	(23) 489	(26) 2704	(27)
NHL 300	(26) 341	(26) 677	(27) 531	(27) 326	(26) 219	(18) 400	(20) 2794	(24)
Other	lymphoprolifera‐
tive	diseases
193	(27) 241	(24) 399	(24) 424	(27) 311	(27) 135	(19) 368	(22) 2071	(24)
Patients	cared	for	with	hypogammaglobulinemia	(IgG	<	4	g/L),	n	(%	of	patients)
CLL 369	(32) 433	(36) 631	(34) 911	(36) 438	(36) 366	(27) 609	(31) 3721	(33)
MM 241	(24) 446	(36) 403	(25) 720	(35) 339	(34) 405	(32) 505	(27) 3043	(30)
NHL 247	(22) 362	(28) 593	(24) 490	(25) 347	(28) 173	(14) 478	(24) 2669	(23)
Other	lymphoprolifera‐
tive	diseases
196	(28) 331	(32) 365	(22) 379	(24) 319	(28) 112	(16) 396	(23) 2086	(25)
CLL,	chronic	lymphocytic	leukemia;	MM,	multiple	myeloma;	NHL,	non‐Hodgkin	lymphoma.
aIncludes	four	physicians	classified	as	allergists/immunologists.	
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2  | METHODS
The	 online	 survey	 was	 conducted	 in	 January	 and	 February	 2018	
and	was	open	to	physicians	from	the	United	States,	Canada,	the	UK,	
France,	Italy,	Spain,	and	Germany.	Qualified	physicians	included	im‐
munologists,	 hematologists/oncologists,	 internal	 medicine	 special‐
ists,	and	pediatricians.	In	order	to	participate,	all	physicians	had	to	be	
responsible	for	the	diagnosis	of	SID	and	the	prescription	of	Ig	treat‐
ment	in	patients	with	hematological	malignancies.	Additionally,	he‐
matologists	and	oncologists	had	to	have	cared	for	at	least	20	patients	
with	hematological	malignancies	over	the	last	12	months.	For	other	
medical	specialties,	 the	minimal	number	of	patients	cared	for	with	
hematological	malignancies	 over	 the	 last	 12	months	was	 five.	 The	
survey	questionnaire	is	provided	as	a	Supplementary	Material.	Data	
used	with	permission	from	third‐party	source.	All	rights	reserved.
3  | RESULTS
3.1 | Survey population
In	total,	230	physicians	from	the	United	States	(N	=	50),	Canada,	the	
UK,	France,	Italy,	Spain,	and	Germany	(N	=	30	each)	participated	in	
the	survey	(Table	1).	Hematologists/oncologists	represented	at	least	
50%	of	 physicians	 in	 all	 countries	 and	90%	of	 all	 participants	 had	
5	years	of	clinical	experience	or	more.	Overall,	surveyed	physicians	
spent	 the	major	part	 of	 their	 time	 in	university/teaching	hospitals	
and	less	in	other	hospitals,	private	practices,	and/or	outpatient	clin‐
ics.	Of	 all	 participants,	 59%	 (N	=	135)	 practiced	exclusively	 in	one	
care	setting	with	64%	of	those	(N	=	87)	working	exclusively	in	uni‐
versity/teaching	hospitals.
Immunologists	 represented	 14%	 (N	=	32)	 of	 all	 physicians	 and	
were	mainly	based	in	the	United	States	(31%)	and	Spain	(28%).	The	
number	of	patients	with	CLL,	MM,	and	NHL	cared	 for	was	similar	
across	all	countries,	indicating	that	the	survey	was	not	influenced	by	
indication	bias.
3.2 | Recurring infections
On	 average,	 CLL	 and	MM	 patients	 were	 more	 likely	 to	 develop	
severe	or	 recurring	 infections	 (30%	and	27%)	 than	patients	with	
NHL	 or	 other	 lymphoproliferative	 diseases	 (24%	 each;	 Table	 1).	
Similarly,	 CLL	 and	MM	patients	were	more	 likely	 to	 develop	 hy‐
pogammaglobulinemia	(33%	and	30%),	defined	as	IgG	levels	<4	g/L,	
than	those	with	NHL	or	other	 lymphoproliferative	diseases	 (23%	
and	 25%).	 There	 was	 some	 variation	 across	 countries	 (Table	 1).	
Hematopoietic	 stem	 cell	 transplantation	 (HSCT)	 was	 performed	
in	14%,	25%,	19%,	and	15%	of	patients	with	CLL,	MM,	NHL,	and	
other	 lymphoproliferative	 diseases,	 respectively.	 Patients	 with	
MM	 and	 NHL	 received	 autologous	 HSCT	 (73%	 and	 69%)	 much	
more	frequently	than	allogenic	HSCT	(27%	and	31%).	Patients	with	
CLL	or	other	 lymphoproliferative	diseases	underwent	autologous	
(51%	and	57%)	and	allogenic	(49%	and	43%)	HSCT	in	comparable	
proportions.	 HSCT	 status	 had	 little	 impact	 on	 reported	 rates	 of	
severe	or	recurring	infections	(average	of	26%‐32%	across	all	dis‐
eases)	 and	hypogammaglobulinemia	 (average	of	24%‐30%	across	
all	diseases).
3.3 | Monitoring and diagnostic practice
Overall,	 serum	 Ig	 levels	were	measured	 in	 83%	 of	MM	 patients,	
76%	 of	 CLL	 patients,	 69%	 of	NHL	 patients,	 and	 69%	 of	 patients	
with	other	lymphoproliferative	diseases	(Table	2).	Ig	levels	in	NHL	
patients	 or	 with	 other	 lymphoproliferative	 diseases	 were	 more	
frequently	measured	by	physicians	spending	at	 least	50%	of	their	
time	in	the	university	setting	in	Canada,	Spain,	and	Italy	(in	about	
80%	of	 their	 patients).	Nearly	 all	 physicians	measured	 IgG	 levels	
(92%‐100%	across	all	countries),	and	most	physicians	measured	IgA	
and	 IgM	 levels	 (68%‐90%	 across	 all	 countries;	 Table	 2).	 IgG	 sub‐
classes	 were	 frequently	 measured	 by	 physicians	 in	 Spain	 (60%),	
Italy	 (43%),	and	the	United	States	 (40%),	and	by	nearly	a	 third	of	
physicians	in	Germany,	Canada,	and	the	UK.	Most	physicians	(82%)	
F I G U R E  1   Infection	prophylaxis	across	all	countries	in	patients	with	hypogammaglobulinemia	(USA	[N	=	50],	Canada,	the	UK,	France,	
Italy,	Spain,	and	Germany	[N	=	30	each])
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measured	Ig	serum	levels	in	all	patients	after	two	or	more	severe	in‐
fections,	68%	and	69%	of	physicians	measured	Ig	before	and	after	
hematopoietic	stem	cell	transplantation	and	64%	after	first	severe	
infection	(Table	2).
The	measurement	of	specific	antibody	responses	varied	across	
countries	 (Table	 2).	 Over	 one‐third	 of	 respondents	 (38%)	 did	 not	
measure	 specific	 antibody	 responses	 in	 general.	 Spanish,	 Italian,	
and	 USA	 physicians	 measured	 specific	 antibody	 responses	 more	
frequently	than	physicians	overall,	probably	due	to	the	higher	pro‐
portion	of	immunologists	in	these	countries	included	in	the	survey.	
Specific	antibody	responses	were	mostly	measured	before	and	after	
vaccination	(referred	to	as	test	immunization).
Specifically,	overall,	33%	of	respondents	performed	test	immu‐
nization	 with	 high	 variability	 observed	 between	 countries.	 While	
Italian	 (43%),	 Spanish	 (53%),	 and	 Canadian	 (43%)	 physicians	 per‐
formed	test	immunization	more	frequently	than	the	average,	in	the	
UK	(17%),	Germany	(20%),	and	France	(23%),	test	immunization	was	
particularly	rare.
3.4 | Choice of infection prophylaxis
Prophylactic	 IgRT	 in	 patients	 with	 hypogammaglobulinemia	 was	
mostly	prescribed	after	two	or	more	severe	infections	(85%	of	phy‐
sicians)	or	after	the	first	severe	infection	(65%	of	physicians;	Figure	1	
and	Table	S1).	IgRT	prescription	practice	was	generally	comparable	
across	most	countries,	but	 there	was	some	variation	 (Table	S1).	 In	
Italy,	Germany,	Spain,	and	the	United	States,	Ig	use	in	patients	with	
hypogammaglobulinemia	 was	 generally	 above	 average.	 The	 com‐
bined	use	of	Ig	and	antibiotics	was	slightly	more	widespread	in	the	
United	 States	 compared	 with	 Europe.	 Concomitant	 use	 of	 Ig	 and	
antibiotics	was	particularly	rare	in	the	UK,	where	Ig	use	was	much	
less	 pronounced	 and	 antibiotic	 use	was	much	more	prominent.	 In	
the	UK,	only	3%	or	less	physicians	used	both	antibiotics	and	Ig	after	
insufficient	vaccination	 response	against	pneumococcus,	after	any	
infection,	and	after	lower	respiratory	tract	infection.	The	combina‐
tion	of	 Ig	and	antibiotics	was	half	 as	 frequent	 in	 the	UK	after	 the	
first	severe	infection	(17%)	and	after	two	or	more	severe	infections	
(30%)	compared	with	the	average	across	all	countries	(36%	and	60%,	
respectively).
3.5 | Treatment with IgRT by indication
The	average	proportion	of	patients	reportedly	treated	with	Ig	alone	
and/	or	in	parallel	with	antibiotics	was	comparable	across	CLL	(32%),	
MM	 (33%),	 NHL	 (25%),	 and	 other	 lymphoproliferative	 diseases	
(26%),	 with	 approximately	 one‐quarter	 to	 one‐third	 of	 patients	
being	 treated	 across	 each	 indication	 (Figure	 2).	 There	were	 some	
regional	 differences	 in	 the	 frequency	 of	 IgRT	 across	 indications.	
Patients	in	Italy	and	the	United	States	were	more	frequently	treated	
with	Ig	across	all	indications.	In	the	UK,	considerably	fewer	patients	
received	 IgRT,	 particularly	 in	 NHL	 (11%)	 and	 other	 lymphoprolif‐
erative	 diseases	 (6%).	 In	 contrast,	 patients	 in	 Italy	 and	 the	United	
States	were	more	 frequently	 treated	with	 Ig	across	all	 indications.	
Furthermore,	US	physicians	practicing	at	least	50%	of	their	time	in	
F I G U R E  2  Average	proportion	of	patients	with	(A)	chronic	lymphocytic	leukemia,	(B)	multiple	myeloma,	(C)	non‐Hodgkin	lymphoma,	and	
(D)	other	lymphoproliferative	diseases,	treated	with	Ig,	with	or	without	antibiotics	in	parallel	over	the	last	12	mo.	The	dashed	line	indicates	
the	average	of	patients	treated	with	Ig,	with	or	without	antibiotics	in	parallel	across	all	countries	(CLL	[32%],	MM	[33%],	NHL	[25%],	and	
other	lymphoproliferative	diseases	[26%]).	Patients	referred	for	Ig	treatment	are	excluded,	as	for	these	patients	no	information	on	antibiotic	
usage	was	available.	The	values	for	average	proportion	of	patients	treated	with	Ig	differed	marginally	when	including	referred	patients
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university	hospitals	treated	a	higher	number	of	patients	with	Ig	ther‐
apy	compared	to	the	average	(CLL:	42%,	MM:	36%,	NHL:	54%,	other	
lymphoproliferative	diseases:	59%).
3.6 | Route of administration and dose
The	reported	use	of	SCIG	was	highest	in	France	(34%)	followed	by	
the	 United	 States	 (30%),	 Italy	 (27%),	 and	 Germany	 (25%).	 Lowest	
SCIG	use	was	reported	in	Spain	(19%)	preceded	by	the	UK	(21%)	and	
Canada	(22%).	The	average	initial	monthly	starting	dose	of	IgG	was	
0.35	g/kg	body	weight	(BW).	Higher	doses	of	0.4‐0.5	g/kg	BW	were	
prescribed	by	70%	of	immunologists	(n	=	32).	No	substantial	differ‐
ences	were	observed	between	countries.
3.7 | Duration of treatment
Over	 80%	 of	 physicians	 prescribed	 Ig	 regardless	 of	 the	 season.	
The	reported	mean	Ig	treatment	duration	was	comparable	across	
countries	 and	 indications	with	 10‐12	months,	 ranging	 from	 1	 to	
60	months	 (Table	 S2).	 Physicians	 in	 Italy	 reported	 the	 shortest	
treatment	durations	across	all	indication	with	a	mean	of	7	months,	
probably	due	to	tighter	cost	control	in	these	countries.	The	main	
reasons	 reported	 for	 discontinuing	 Ig	 therapy	were	 no	 infection	
for	 12	months	 and	 adequate	 specific	 antibody	 response	 by	39%	
of	physicians,	 followed	by	no	 infections	 for	6	months	by	26%	of	
physicians.	 IgG	 trough	 levels	 were	 reported	 as	 the	main	 reason	
for	discontinuing	 Ig	 therapy	by	17%	of	all	physicians	but	37%	of	
French	physicians.
3.8 | Immunologist responses
Immunologists	followed	recommendations	more	closely	than	oncol‐
ogists/hematologists	overall.	Only	6%	of	immunologists	(n	=	32)	did	
not	measure	specific	antibody	responses	compared	to	38%	of	phy‐
sicians.	Over	two‐thirds	of	immunologists	reported	performing	test	
immunizations	 whereas	 only	 one‐third	 of	 physicians	 did	 (Table	 2).	
Immunologists	prescribed	Ig	in	more	patients	(CLL:	63%,	MM:	54%,	
NHL:	47%,	other:	27%),	than	physicians	(CLL:	32%,	MM:	33%,	NHL:	
25%,	other:	26%),	possibly	because	most	patients	were	referred	to	
the	immunologists	specifically	for	Ig	treatment.	Immunologists	also	
used	 Ig	more	 often	 than	 physicians	 before	 any	 infection	 occurred	
and	 when	 vaccination	 responses	 were	 insufficient.	 Immunologists	
used	higher	doses	of	 IgG,	with	70%	using	 initial	monthly	doses	of	
0.4‐0.5	g/kg	BW	compared	with	45%	of	physicians	across	all	coun‐
tries.	Immunologists	also	used	SCIG	more	frequently	than	physicians	
(44%	vs	25%).
4  | DISCUSSION
Two	recent	publications	reported	data	on	the	management	of	SID	in	
patients	with	malignancies:	the	prospective,	observational	German	
SIGNS	 study,	 and	 a	 survey	 among	British	 and	 Irish	 immunologists	
on	the	prescription	practice	of	IgRT	in	SID.23,24	The	present	online	
survey	of	230	physicians	identifies	a	discrepancy	between	approved	
indications,	 published	 recommendations,	 and	 daily	 routine	 in	 the	
treatment	of	SID	in	patients	with	hematological	malignancies	on	an	
international	level.
Approved	 indications	 for	 Ig	 products	 differ	 between	 countries.	
In	Canada,	 IVIG	and	SCIG	 concentrates	 are	 generally	 indicated	 for	
use	 in	 SID.25,26	 In	 the	EU,	 as	of	2019	 the	 approved	 indications	 for	
IVIG	in	SID	have	been	widened	from	patients	with	CLL,	MM	and	pa‐
tients	 after	 allogeneic	 hematopoietic	 stem	 cell	 transplantation,28,29 
to	patients	who	suffer	from	severe	or	recurrent	bacterial	infections,	
ineffective	antibiotic	treatment	and	either	proven	specific	antibody	
failure	(failure	to	mount	at	least	a	two‐fold	rise	in	IgG	antibody	titer	to	
pneumococcal	polysaccharide	and	polypeptide	antigen	vaccines)	or	
serum	IgG	level	of	<4	g/L.30	In	the	USA,	only	a	single	Ig	concentrate	is	
approved	for	use	in	CLL.31	No	other	products	are	approved	for	other	
hematological	malignancies,	and	SCIG	is	only	approved	for	PID.32
National	recommendations	for	the	use	of	IgRT	in	SID	in	patients	
with	hematological	malignancies	are	generally	not	aligned	with	the	
approved	 indications	 in	 the	 corresponding	 country.	 For	 example,	
in	 the	United	States,	 the	American	Academy	of	Allergy,	Asthma	&	
Immunology	 (AAAAI)	 recommend	 that	 treatment	 should	 be	 con‐
sidered	 in	 patients	 with	 CLL	 or	 MM,	 after	 lymphoma	 treatment	
with	B‐cell‐depleting	therapies,	and	 in	patients	who	are	hypogam‐
maglobulinemic	with	 recurrent	bacterial	 infections	 and	 subprotec‐
tive	antibody	levels	after	immunization	against	diphtheria,	tetanus,	
or	pneumococcal	 infection.32	 In	Germany,	prophylactic	use	of	 Ig	 is	
recommended	 in	hypogammaglobulinemic	patients	with	malignant	
lymphoma,	MM,	and	chronic	immunosuppression	with	at	least	three	
severe	 bacterial	 infections	 in	 the	 respiratory,	 gastrointestinal,	 or	
urogenital	system	or	sepsis	per	year.33	In	the	UK,	the	Department	of	
Health	recommended	selection	criteria	for	IgRT	of	hypogammaglob‐
ulinemia	associated	with	non‐Hodgkin	lymphoma	(NHL),	CLL,	MM,	
or	other	relevant	B‐cell	malignancy	in	combination	with	recurrent	or	
severe	bacterial	infection	despite	continuous	oral	antibiotic	therapy	
for	 3	months,	 IgG	 <5	g/L	 (excluding	 paraprotein)	 and	 documented	
failure	of	serum	antibody	response	to	unconjugated	pneumococcal	
or	other	polysaccharide	vaccine	challenge.	In	Canada,	prophylactic	
IVIG	is	recommended	in	adult	patients	with	hematologic	malignan‐
cies	who	have	had	a	 recent	 life‐threatening	 infection	or	 recurrent	
episodes	of	clinically	significant	infections	(eg,	pneumonia),	if	these	
infections	are	thought	to	be	caused	by	low	levels	of	polyclonal	Ig.22
Treatment	 application	 was	 comparable	 across	 the	 countries,	
indicating	 that	 country‐specific	 approval	 status	of	 Ig	 concentrates	
does	 not	 influence	 the	 daily	 practice	 of	 physicians.	 Despite	 IgRT	
not	being	approved	for	malignancies	other	 than	CLL	 in	 the	United	
States	and	additionally	for	MM	in	Europe	at	the	time	of	the	survey,	
serum	Ig	 levels	were	widely	monitored	across	CLL,	MM,	NHL,	and	
other	 lymphoproliferative	 diseases	 and	 IgRT	 administered	 across	
all	these	malignancies.	In	the	United	States,	which	has	the	most	re‐
stricted	 indication,	 IgRT	was	prescribed	equally	 in	CLL,	MM,	NHL,	
and	other	lymphoproliferative	diseases	and	used	considerably	more	
frequently	within	each	 indication	 than	generally	 in	Europe	 (except	
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in	 Italy)	and	Canada	(Figure	2).	 In	addition,	30%	of	USA	physicians	
prescribed	SCIG,	despite	it	not	being	approved	in	SID.	These	data	in‐
dicate	harmonization	of	clinical	practice,	despite	regional	indication	
differences	and	the	lack	of	harmonized	treatment	guidelines.
Although	Ig	levels	were	generally	monitored	in	NHL	and	other	
lymphoproliferative	diseases,	a	significant	proportion	of	this	sub‐
population	was	reported	to	develop	severe	or	recurring	infections.	
In	addition,	in	Canada,	France,	Germany,	and	the	UK,	the	reported	
proportion	 of	 patients	 with	 NHL	 receiving	 infection	 prophylaxis	
with	 Ig	 was	 considerably	 lower	 than	 the	 proportion	 of	 patients	
with	 severe	 or	 recurring	 infections.	 This	 indicates	 that	 patients	
in	 this	 population	 could	potentially	 benefit	 from	 IgRT	 and	 an	 in‐
creased	awareness	of	the	risk	of	 infection	due	to	SID.	University	
physicians	generally	prescribed	IgRT	more	frequently,	possibly	be‐
cause	they	were	 likely	to	be	dealing	with	patients	suffering	from	
more	severe	infections	and	access	to	Ig	therapy	might	have	been	
easier	at	university	hospitals.
The	 abovementioned	 off‐label	 use	 of	 IgRT	 and	 the	 potentially	
unaddressed	Ig‐eligible	population	indicate	a	need	to	extend	the	in‐
dications	for	IgRT	in	SID	in	Europe	and	the	USA,	and	to	increase	the	
awareness	for	the	risk	of	SID	beyond	CLL	and	MM.
A	 recent	 expert	 opinion	 on	 prophylactic	 IgRT	 in	 SID	 recom‐
mended	 against	 routine	 measurement	 of	 IgG	 subclasses	 due	 to	
the	 low	 incidence	of	pure	 IgG	subclass	deficiency	and	the	 limited	
evidence	for	correlation	between	infection	rates	and	low	levels	of	
IgG	subclasses	in	patients	with	normal	IgG	levels.11	In	contrast,	phy‐
sicians	 frequently	measured	 IgG	 subclasses,	 particularly	 in	 Spain,	
Italy,	and	the	United	States.	This	expert	opinion	and	a	recent	review	
on	IgRT	in	hematological	malignancy	stressed	the	importance	of	as‐
sessing	and	monitoring	specific	antibody	responses.11,34	In	this	on‐
line	survey,	over	one‐third	of	respondents	did	not	measure	specific	
antibody	 responses,	 while	 immunologists	 were	much	more	 likely	
to	 measure	 specific	 antibody	 responses.	 Contrary	 to	 recommen‐
dations	 to	 systematically	 perform	 test	 immunizations	 in	 patients	
with	 SID,	 only	 one‐third	 (33%)	 of	 surveyed	 physicians	 did	 so	 on	
average.11	Over	two‐thirds	(68%)	of	immunologists	performed	test	
immunizations,	which	 is	 in	 line	with	 the	data	 reported	 for	British	
and	Irish	immunologists.24	These	data	indicate	that	immunologists	
follow	the	recommendations	more	closely.	However,	there	is	no	ev‐
idence	that	increased	monitoring	results	in	improved	outcomes	(or	
less	infection	or	decreased	mortality)	since	supporting	clinical	data	
are	lacking.
In	 contrast	 to	 German	 recommendations	 to	 initiate	 IgRT	 after	
at	least	three	severe	bacterial	infections	per	year,33	German	physi‐
cians	frequently	prescribed	prophylactic	IgRT	after	the	first	severe	
infection	(67%),	after	lower	respiratory	infection	(50%),	after	any	in‐
fection	occurs	 (47%),	 and	even	before	 any	 infection	occurs	 (33%).	
These	 data	 are	 in	 line	with	 findings	 of	 the	 German	 observational	
prospective	SIGNS	study,	which	reported	that	most	of	the	patients	
newly	treated	with	IgRT	did	not	fulfill	the	German	recommendations	
regarding	the	frequency	of	severe	infections.23	This	divergence	be‐
tween	recommendations	and	clinical	practice	points	to	the	need	for	
clinical	studies	to	evaluate	the	use	of	IgRT	at	an	early	stage	in	a	pa‐
tient’s	primary	disease,	as	suggested	previously.11,34
The	 high	 reported	 use	 of	 prophylactic	 antibiotics	 in	 the	UK	 is	
consistent	with	 reports	 of	 85%	of	British	 and	 Irish	 immunologists	
prescribing	prophylactic	antibiotics	in	all,	or	most,	of	their	patients	
before	starting	Ig	therapy.24	These	observations	might	be	explained	
by	the	 inclusion	of	recurrent	or	severe	bacterial	 infections	despite	
continuous	oral	antibiotic	therapy	for	3	months	as	selection	criteria	
for	IgRT	in	the	British	clinical	guidelines	for	Ig	use.35
The	reported	use	of	SCIG	was	unexpectedly	high,	ranging	from	
19%	to	34%.	These	numbers	seem	an	overestimation	of	the	actual	
use	in	these	countries.	For	example,	6.5%	of	patients	received	SCIG	
in	the	recent	German	SIGNS	study.23	Regional	differences	may	be	a	
consequence	of	national	reimbursement	policies.
The	 average	 initial	monthly	 starting	dose	of	 IgG	was	0.35	g/
kg	 BW,	 which	 lies	 in	 the	 range	 of	 0.2‐0.4	g/kg	 BW	 stated	 in	
most	 guidelines.	 In	 Europe,	 a	 dose	 of	 0.2‐0.4	g/kg	 BW	 every	
3‐4	weeks	 is	 recommended	 in	 the	 current	 IVIG	 core	 Summary	
of	 Product	 Characteristics.30	 Similarly,	 Canadian	 recommen‐
dations	 state	 0.4	g/kg	 BW	 every	 3	weeks	 with	 re‐evaluation	
every	 4‐6	months.22	 In	 contrast,	 UK	 clinical	 guidelines	 for	 Ig	
use	 (Department	 of	Health)	 have	modified	 the	 dose	 recommen‐
dation	 from	0.4	g/kg	 BW/mo	 to	 “achieve	 an	 IgG	 trough	 level	 of	
at	 least	 the	 lower	 limit	 of	 the	 age‐specific	 serum	 IgG	 reference	
range,”	while	British	guidelines	for	supportive	care	in	MM	suggest	
a	dose	of	IVIG	of	0.5	g/kg	BW	administered	every	month	for	up	to	
6	months.35,36	 Immunologists	 (n	=	32)	 tended	to	prescribe	higher	
doses	 of	 IgG	 than	 other	 physicians,	with	 70%	of	 them	prescrib‐
ing	doses	in	the	range	of	0.4‐0.5	g/kg	BW.	High	doses	may	result	
from	extrapolation	of	dosing	in	PID,	which	may	be	expected	in	the	
absence	of	clear	guidelines	in	SID.	In	contrast	to	our	findings,	aver‐
age	monthly	doses	prescribed	in	Germany	were	recently	reported	
to	be	around	0.2	g/kg	BW.23
Comparable	 to	 numbers	 reported	 for	 clinical	 practice	 in	
Germany,23	over	80%	of	physicians	used	IgRT	regardless	of	season.	
This	contrasts	with	recommendations	by	Agostini	et	al11	who	sug‐
gest	 seasonal	 discontinuation	 of	 treatment	 during	 late	 spring	 and	
summer	months.	 In	 line	with	 recommendations	were	 the	 reported	
duration	of	10‐12	months	and	the	reported	main	reasons	for	discon‐
tinuing	Ig	therapy,	no	infection	for	12	months	and	adequate	specific	
antibody	response.11
Notably,	data	were	collected	from	physicians	rather	than	from	
patient	 records.	 In	 addition,	 the	proportion	of	patients	with	hy‐
pogammaglobulinemia	 and/	 or	 severe	 infections	 as	 separate	 or	
concomitant	events	was	not	analyzed.	Furthermore,	it	might	be	of	
interest	to	further	stratify	the	reported	data	by	diseases	grouped	
as	 “other	 lymphoproliferative	 diseases.”	 This	 study	 did	 not	 cap‐
ture	 data	 on	 chemotherapeutic	 medication	 used	 to	 treat	 the	
different	hematological	malignancies.	 In	 future	 studies,	 it	would	
be	 interesting	 to	assess	how	different	B‐cell	 targeting	 therapies	
across	 the	 investigated	disease	entities	 impact	on	 the	 incidence	
and	management	of	SID.
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5  | CONCLUSIONS
The	 survey	 revealed	 discrepancies	 among	 daily	 practice,	 clinical	
practice,	guideline	recommendations,	and	currently	approved	 indi‐
cations.	This	underlines	 the	medical	need	 for	more	evidence	 from	
robust	clinical	trials,	especially	in	hematological	malignancies	other	
than	CLL	and	MM,	in	order	to	optimize	the	risk	stratification	of	pa‐
tients	and	to	guide	the	identification	of	those	patients	likely	to	ben‐
efit	from	IgRT.
Despite	 regional	 indication	 differences,	 IgRT	 use	 was	 overall	
comparable	 across	 the	 countries.	 Moreover,	 although	 IgRT	 is	 not	
indicated	 for	 SID	 in	 hematological	malignancies	other	 than	CLL	 in	
the	 United	 States	 and	 CLL	 and	MM	 in	 Europe,	 physicians	 widely	
used	 IgRT	 in	 MM,	 NHL,	 and	 other	 hematological	 diseases.	 High	
regional	 variability	 and/or	 deviations	 from	 current	 treatment	 rec‐
ommendations	were	observed	in	the	monitoring	of	IgG	subclasses,	
measurement	of	 specific	 antibody	 responses,	 performance	of	 test	
immunization,	 and	 treatment	duration.	Overall,	 immunologists	 fol‐
lowed	 recommendations	 to	 measure	 specific	 antibody	 responses	
and	perform	test	 immunizations	much	more	closely	 than	hematol‐
ogists/oncologists,	 suggesting	 that	 closer	 collaboration	 between	
immunologists	and	hematologist/oncologists	could	be	beneficial	for	
the	management	of	SID.	This	large,	international	survey	of	different	
specialists	 involved	 in	 the	 care	of	 patients	with	malignancies	with	
SIDs	demonstrated	that	harmonized	evidence‐based	diagnostic	and	
treatment	guidelines	in	SID	in	hematological	diseases	are	needed.
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